The FDA combination therapy approval of dolutegravir and rilpivirine is indicated for adults with HIV-1 bacterial infections whose virus is currently suppressed (Administration of high doses of tenofovir has been claimed to generate bone toxicity claimed as osteomalacia and minimized bone mineral density and to create some degree of renal toxicity.